PUMA BIOTECHNOLOGY, INC. Interest Expense
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Interest Expense of $3.36 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-02.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-05-02
- PUMA BIOTECHNOLOGY, INC. interest expense for the quarter ending 2024-03-31 was $3.36M, a 1.42% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. interest expense for the quarter ending 2023-12-31 was $3.35M, a 2.29% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. interest expense for the quarter ending 2023-09-30 was $3.34M, a 13.30% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. interest expense for the quarter ending 2023-06-30 was $3.33M, a 23.06% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. interest expense for fiscal 2023 was $13.33M, a 14.99% increase from fiscal 2022.
- PUMA BIOTECHNOLOGY, INC. interest expense for fiscal 2022 was $11.59M, a 9.49% decline from fiscal 2021.
- PUMA BIOTECHNOLOGY, INC. interest expense for fiscal 2021 was $12.81M, a 8.82% decline from fiscal 2020.
- PUMA BIOTECHNOLOGY, INC. interest expense for fiscal 2020 was $14.05M, a 6.48% decline from fiscal 2019.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $3.36M 10-Q · filed 2024-05-02 | $6.71M derived: sum of 2 quarters · filed 2024-05-02 | $10.05M derived: sum of 3 quarters · filed 2024-05-02 | $13.38M derived: sum of 4 quarters · filed 2024-05-02 |
| 2023-12-31 | $3.35M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $6.69M derived: sum of 2 quarters · filed 2024-02-29 | $10.02M derived: sum of 3 quarters · filed 2024-02-29 | $13.33M 10-K · filed 2024-02-29 |
| 2023-09-30 | $3.34M 10-Q · filed 2023-11-02 | $6.66M derived: sum of 2 quarters · filed 2023-11-02 | $9.98M 10-Q · filed 2023-11-02 | $13.26M derived: sum of 4 quarters · filed 2024-05-02 |
| 2023-06-30 | $3.33M 10-Q · filed 2023-08-03 | $6.64M 10-Q · filed 2023-08-03 | $9.92M derived: sum of 3 quarters · filed 2024-05-02 | $12.86M derived: sum of 4 quarters · filed 2024-05-02 |
| 2023-03-31 | $3.31M 10-Q · filed 2024-05-02 | $6.59M derived: sum of 2 quarters · filed 2024-05-02 | $9.54M derived: sum of 3 quarters · filed 2024-05-02 | $12.24M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $3.28M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $6.23M derived: sum of 2 quarters · filed 2024-02-29 | $8.93M derived: sum of 3 quarters · filed 2024-02-29 | $11.59M 10-K · filed 2024-02-29 |
| 2022-09-30 | $2.95M 10-Q · filed 2023-11-02 | $5.65M derived: sum of 2 quarters · filed 2023-11-02 | $8.31M 10-Q · filed 2023-11-02 | $11.03M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $2.70M 10-Q · filed 2023-08-03 | $5.37M 10-Q · filed 2023-08-03 | $8.08M derived: sum of 3 quarters · filed 2024-02-29 | $11.21M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $2.66M 10-Q · filed 2023-05-04 | $5.38M derived: sum of 2 quarters · filed 2024-02-29 | $8.50M derived: sum of 3 quarters · filed 2024-02-29 | $12.02M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $2.72M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $5.84M derived: sum of 2 quarters · filed 2024-02-29 | $9.36M derived: sum of 3 quarters · filed 2024-02-29 | $12.81M 10-K · filed 2024-02-29 |
| 2021-09-30 | $3.12M 10-Q · filed 2022-11-03 | $6.64M derived: sum of 2 quarters · filed 2022-11-03 | $10.09M 10-Q · filed 2022-11-03 | $13.66M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-06-30 | $3.52M 10-Q · filed 2022-08-04 | $6.97M 10-Q · filed 2022-08-04 | $10.54M derived: sum of 3 quarters · filed 2023-03-02 | $14.16M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-03-31 | $3.45M 10-Q · filed 2022-05-05 | $7.02M derived: sum of 2 quarters · filed 2023-03-02 | $10.64M derived: sum of 3 quarters · filed 2023-03-02 | $14.43M derived: sum of 4 quarters · filed 2023-03-02 |
| 2020-12-31 | $3.57M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $7.19M derived: sum of 2 quarters · filed 2023-03-02 | $10.98M derived: sum of 3 quarters · filed 2023-03-02 | $14.05M 10-K · filed 2023-03-02 |
| 2020-09-30 | $3.63M 10-Q · filed 2021-11-04 | $7.41M derived: sum of 2 quarters · filed 2021-11-04 | $10.48M 10-Q · filed 2021-11-04 | $13.55M derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-06-30 | $3.78M 10-Q · filed 2021-08-05 | $6.85M 10-Q · filed 2021-08-05 | $9.93M derived: sum of 3 quarters · filed 2022-03-03 | $12.98M derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-03-31 | $3.07M 10-Q · filed 2021-05-06 | $6.14M derived: sum of 2 quarters · filed 2022-03-03 | $9.20M derived: sum of 3 quarters · filed 2022-03-03 | $13.64M derived: sum of 4 quarters · filed 2022-03-03 |
| 2019-12-31 | $3.08M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $6.13M derived: sum of 2 quarters · filed 2022-03-03 | $10.58M derived: sum of 3 quarters · filed 2022-03-03 | $15.02M 10-K · filed 2022-03-03 |
| 2019-09-30 | $3.05M 10-Q · filed 2020-11-05 | $7.50M derived: sum of 2 quarters · filed 2020-11-05 | $11.94M 10-Q · filed 2020-11-05 | $15.76M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $4.45M 10-Q · filed 2020-08-06 | $8.89M 10-Q · filed 2020-08-06 | $12.71M derived: sum of 3 quarters · filed 2021-03-01 | $16.21M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $4.44M 10-Q · filed 2020-05-07 | $8.26M derived: sum of 2 quarters · filed 2021-03-01 | $11.76M derived: sum of 3 quarters · filed 2021-03-01 | $14.35M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $3.82M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $7.32M derived: sum of 2 quarters · filed 2021-03-01 | $9.91M derived: sum of 3 quarters · filed 2021-03-01 | $10.98M 10-K · filed 2021-03-01 |
| 2018-09-30 | $3.50M 10-Q · filed 2019-11-07 | $6.09M derived: sum of 2 quarters · filed 2019-11-07 | $7.17M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $2.59M 10-Q · filed 2019-08-09 | $3.67M 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | $1.08M 10-Q · filed 2019-05-10 | |||
| 2017-12-31 | $720.00K 10-K · filed 2020-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |